IL-23 Inhibitor Performance in Psoriatic Disease A single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA. https://t.co/J3HIDBguj1 https://t.co/uqYf0Bdh0n

• https://bit.ly/3DC5jyX

2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic CPPD disease is unknown. https://t.co/yNQkEwRT3W https://t.co/YG7uBpDrPP

• https://bit.ly/476sv65

SGLT2 inhibitor (empagliflozin) given in a lupus mouse (MRL/lpr) model showed a renoprotective effect suggesting the value of non-immunosuppressive therapies to improve renal function. Showed less -dsDNA Abs, proteinuria, renal nephritis damage https://t.co/iPhecsJeJX https://t.co/0TIy2hsPC1

• https://bit.ly/47dWU2o

Link Between Vitamin D and Psoriasis Severity More than 8M people in the US experience psoriasis-a person’s vitamin D levels could play an important role in psoriasis severity, according to one of the largest studies to date. https://t.co/bHnYn87wQS https://t.co/JsloVaxHd4

• https://bit.ly/44L3ICV

Rheumatoid vasculitis (RV) metanalysis: RV decreased sincefrom 9.1 (1988-2000) to 3.9 (2001-2010) per million. RV risk increased w/ smoking, disease duration, seropositivity, males, HLA-DRB104, HLA-C3. Common: skin (65–88%), CNS(35–63%), cardiac (33%) https://t.co/O3G4CS1pdx https://t.co/I2RVKR20lX

• https://bit.ly/43M44aY

Voclosporin in SLE - Long-Term Safety and Efficacy The AURORA 2 study evaluated the long-term safety and efficacy of VOC upus nephritis (LN) patients and, after 3 years, demonstrated long term safety and efficacy following the one-year AURORA 1 study. https://t.co/YmKLuhyCVG https://t.co/X2u9iCckt7

• https://bit.ly/3q6i6Xl

EULAR/ACR Guidance on HLH/MAS A EULAR/ACR task force has established evidence based, up-to-date guidance, and expert opinion on the evaluation, management and monitoring of patients with HLH and MAS. https://t.co/ZQQ75pyvAX https://t.co/t6lj5XaAwB

• https://bit.ly/3Klosce

SGLT2 Inhibitors Reduce Gout Flares and CV Events A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring ED visits or hospitalizations. https://t.co/XCh7ulamwU https://t.co/dbOAtaflmb

• https://bit.ly/3Kg9Bja

JAMA: cutaneous hallmarks of dermatomyositis. Printable Patient education overview. https://t.co/8U6DHbJybE https://t.co/e45KCd5gBL

• https://bit.ly/452tVws

MMWR: Arthritis Among Children and Adolescents The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021. https://t.co/S1dG60jJ1J https://t.co/rKQ64sopl2

• https://bit.ly/43MCZ7x

RNase Treatment of Autoimmune Disorders U1RNP complex, Ro/SSA and La/SSB are major RNA-containing autoantigens associated with autoimmune disorders. https://t.co/RuXV3uAVz7 https://t.co/rWaKlmPnEe

• https://bit.ly/43NGACg

Tofactitinib in PsA & RA: Nine Year Safety Data A real-world, post-marketing surveillance (PMS) of tofacitinib in PsA and RA shows a consistent pattern of safety with no new safety concerns identified. https://t.co/erBi7JJtCY https://t.co/9tU361FkfU

• https://bit.ly/3qdssof

Time to live your life. Do the right thing, make a difference, leave an imprint.. https://t.co/LEY7bFcV2S

Horizon announced its phase II RCT of Daxdilimab (anti-ILT7 mAB targeting dendritic cells) failed to meet its primary endpoint - BICLA response w/ pred ≤7.5 mg/day @wk48 (DAX=PBO). DAX also under study in alopecia areata, DLE, lupus nephritis https://t.co/8zDCWI5vB1 https://t.co/pVIg4ctvC5

• https://bit.ly/3DEsHeY

Unrecognized Mental Health Problems in Autoimmune Diseases More than half of patients with auto-immune conditions experience mental health conditions such as depression or anxiety, yet most are rarely asked in clinic about mental health symptoms. https://t.co/wxuGmuPh7D https://t.co/jMZkH1SIcS

• https://bit.ly/476luC7